
Non-radiographic axial spondyloarthritis (AXSPA) Program in Pharmaceutical Benefits Scheme (PBS) 012-18112216

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of the Pharmaceutical Benefits Scheme
(PBS) subsidised biological agents for patients with non-radiographic
axial spondyloarthritis.

AXSPA and listing dates

Non-radiographic axial spondyloarthritis (AXSPA) is a type of
inflammatory disease of the joints that does not display the classic
features on radiographic tests.

Listing dates:

-   golimumab - 1 December 2018
-   certolizumab pegol - 1 June 2020
-   secukinumab - 1 April 2021

See Written Authority Required Drugs for further information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS - Complex
Drugs Programs team, and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item codes, restriction, the Pharmaceutical Benefits Scheme (PBS) and
the Services Australia websites.

Related links

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)

Processing and National Demand Allocation (PaNDA)

Process telephone Authority approval application

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
